| Basics |
Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. The company is engaged in the development and commercialization of therapies for people with rare debilitating diseases, chronic neuromuscular and neurological diseases.
|
| IPO Date: |
October 5, 2001 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$2.89B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.14 | 3.22%
|
| Avg Daily Range (30 D): |
$0.33 | 1.48%
|
| Avg Daily Range (90 D): |
$0.32 | 1.50%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.83M |
| Avg Daily Volume (30 D): |
.95M |
| Avg Daily Volume (90 D): |
1.13M |
| Trade Size |
| Avg Trade Size (Sh.): |
146 |
| Avg Trade Size (Sh.) (30 D): |
59 |
| Avg Trade Size (Sh.) (90 D): |
65 |
| Institutional Trades |
| Total Inst.Trades: |
2,321 |
| Avg Inst. Trade: |
$2.72M |
| Avg Inst. Trade (30 D): |
$3.02M |
| Avg Inst. Trade (90 D): |
$2.83M |
| Avg Inst. Trade Volume: |
.21M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$3.5M |
| Avg Closing Trade (30 D): |
$4.66M |
| Avg Closing Trade (90 D): |
$4.6M |
| Avg Closing Volume: |
272.64K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
$1.78
|
$.43
|
$.43
|
|
Diluted EPS
|
$1.71
|
$.42
|
$.41
|
|
Revenue
|
$ 578.2M
|
$ 148.39M
|
$ 146.56M
|
|
Gross Profit
|
$ 495.37M
|
$ 125.74M
|
$ 125.95M
|
|
Net Income / Loss
|
$ 217.56M
|
$ 52.78M
|
$ 52.11M
|
|
Operating Income / Loss
|
$ 258.78M
|
$ 66.27M
|
$ 66.3M
|
|
Cost of Revenue
|
$ 82.82M
|
$ 22.65M
|
$ 20.61M
|
|
Net Cash Flow
|
$ 247.56M
|
$ 37.09M
|
$ 135.25M
|
|
PE Ratio
|
13.76
|
|
|
|
|
|
